LEVULAN KERASTICK and BLU-U PDT is an in-office therapy that provides high clearance with low downtime for appropriate actinic keratosis patients.*1
Appropriate patient selection requires the evaluation of a range of factors, such as AK lesion characteristics, patient expectations, patient history and patient adherence. Patient adherence is closely linked to treatment outcome which makes patient selection very important in order to reduce risk of nonadherence.2,3
Among the patients at risk for nonadherence are those who:
Among the factors associated with nonadherence are:
Poor medication adherence is reaching crisis proportions in the US2
A 2009 survey by the Senior Citizens League found4
Another survey found5
PDT is an effective therapy that will not only add value for your practice, but it may also be the right treatment choice for your new AK patients or those who are unwilling to repeat a prior topical treatment. In addition, an in-office therapy can impact patient adherence.
* Patients treated with LEVULAN KERASTICK and BLU-U PDT should avoid exposure of the photosensitized lesions to sunlight or prolonged or intense light for at least 40 hours.
** Please consult your local/state regulations.
1 LEVULAN KERASTICK Prescribing Information, DUSA Pharmaceuticals, Inc.
2 Enhancing Prescription Medicine Adherence: A National Action Plan. National Council on Patient Information and Education. August 2007.
3 Gupta G, et al. Adherence to topical dermatological therapy: lessons from oral drug treatment. BR J Dermatol. 209; 161:221-227.
5 Take as Directed: A Prescription Not Followed. Research conducted by The Polling Company™. National Community Pharmacists Association. December 15, 2006.
WEB 1460 Rev E